Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Schilling

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Molecules (Basel, Switzerland)|February 5, 2020
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In VitroJanett Köppen, Anja Schulze, Lisa Machner, et al.
The Journal of Biological Chemistry|January 6, 2021
Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitisNadine Taudte, Miriam Linnert, Jens-Ulrich Rahfeld, et al.
The Lancet. Infectious Diseases|April 28, 2009
Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious DiseasePhilippe Brouqui, Vincenzo Puro, Francesco M Fusco, et al.
The Journal of Biological Chemistry|April 10, 2021
Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitisNadine Taudte, Miriam Linnert, Jens-Ulrich Rahfeld, et al.
Alzheimer'S Research & Therapy|November 15, 2020
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathologyKathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, et al.
Alzheimer'S Research & Therapy|January 15, 2020
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like miceHelen Crehan, Bin Liu, Martin Kleinschmidt, et al.
Nature Medicine|October 7, 2008
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathologyStephan Schilling, Ulrike Zeitschel, Torsten Hoffmann, et al.
Acta Neuropathologica|December 3, 2024
Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementiaSarah Schrempel, Anna Katharina Kottwitz, Anke Piechotta, et al.
Nature|June 5, 2012
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-βJustin M Nussbaum, Stephan Schilling, Holger Cynis, et al.
Acta Neuropathologica|July 26, 2021
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathiesMaike Hartlage-Rübsamen, Alexandra Bluhm, Sandra Moceri, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Molecules (Basel, Switzerland)|February 5, 2020
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In VitroJanett Köppen, Anja Schulze, Lisa Machner, et al.
The Journal of Biological Chemistry|January 6, 2021
Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitisNadine Taudte, Miriam Linnert, Jens-Ulrich Rahfeld, et al.
The Lancet. Infectious Diseases|April 28, 2009
Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious DiseasePhilippe Brouqui, Vincenzo Puro, Francesco M Fusco, et al.
The Journal of Biological Chemistry|April 10, 2021
Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitisNadine Taudte, Miriam Linnert, Jens-Ulrich Rahfeld, et al.
Alzheimer'S Research & Therapy|November 15, 2020
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathologyKathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, et al.
Alzheimer'S Research & Therapy|January 15, 2020
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like miceHelen Crehan, Bin Liu, Martin Kleinschmidt, et al.
Nature Medicine|October 7, 2008
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathologyStephan Schilling, Ulrike Zeitschel, Torsten Hoffmann, et al.
Acta Neuropathologica|December 3, 2024
Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementiaSarah Schrempel, Anna Katharina Kottwitz, Anke Piechotta, et al.
Nature|June 5, 2012
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-βJustin M Nussbaum, Stephan Schilling, Holger Cynis, et al.
Acta Neuropathologica|July 26, 2021
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathiesMaike Hartlage-Rübsamen, Alexandra Bluhm, Sandra Moceri, et al.
Pageof 10